The influence of hyperhomocysteinemia on graft patency after infrainguinal bypass surgery in the Dutch BOA Study  by de Borst, G.J. et al.
The influence of hyperhomocysteinemia on graft
patency after infrainguinal bypass surgery in the
Dutch BOA Study
G. J. de Borst, MD,a M. J. D. Tangelder, MD, PhD,a A. Algra, MD, PhD,b,c J. A. Lawson, MD, PhD,d
J. D. Banga, MD, PhD,e B. C. Eikelboom, MD, PhD,a and J. A. van der Vliet, MD, PhD,f on behalf of
the Dutch BOA Study Group* Nijmegen, The Netherlands
Objective: Hyperhomocysteinemia has been identified as a risk factor for (cardio)vascular disease. Whether hyperhomo-
cysteinemia contributes to graft failure after peripheral bypass surgery remains unclear. The present study evaluated the
influence of hyperhomocysteinemia on graft patency after infrainguinal bypass surgery.
Design: The present study was designed as a nested case-control study.
Method: In this study (nested in the Dutch Bypass Oral anticoagulants or Aspirin Study), 150 patients with graft occlusion
were each matched with two randomly selected controls with patent grafts (N 299) from the same trial. Venous blood
samples were drawn from cases and controls, and total plasma homocysteine (tHcy) was determined. Mean serum
homocysteine levels and the presence of hyperhomocysteinemia (>95th percentile in healthy individuals) were compared
between cases and controls.
Results: No significant differences were found between serum levels of homocysteine in patients with and without graft
occlusion. The mean plasma homocysteine levels were 14.4 mol/L and 14.9 mol/L in the case and control groups,
respectively. The resulting mean difference was 0.4 (95% confidence interval [CI], 1.8-0.9). The odds ratio of
hyperhomocysteinemia was 0.81 (95% CI, 0.49-1.33). Adjustment for risk factors of graft occlusion did not change these
results.
Conclusions: Postoperative raised serum levels of homocysteine proved not to be a risk factor for graft occlusion after
infrainguinal bypass grafting. (J Vasc Surg 2002;36:336-40.)
Patients who have undergone infrainguinal bypass sur-
gery are at risk for graft occlusion. The overall cumulative
2-year incidence of graft occlusion after infrainguinal by-
pass surgery by means of either autologous vein or pros-
thetic grafts approximates 25%.1,2 Technical aspects may be
responsible for early failures, whereas failures in the first
year are caused by progressive graft or anastomotic stenosis
from intimal hyperplasia and subsequent occlusion. The
exact pathogenesis of intimal hyperplasia is not fully under-
stood, but the mechanism may be similar to that of athero-
sclerosis.3
Independent risk factors for infrainguinal bypass graft
occlusion within the Dutch Bypass Oral anticoagulants or
Aspirin (BOA) Study included prior critical ischemia, distal
anastomosis to crural vessels (femorocrural bypass), use of
nonvenous graft material, female gender, and poor runoff
in patients with femoropopliteal bypasses.4 Smoking, dia-
betes mellitus, hypertension, and hyperlipidemia (which are
generally considered to be vascular risk factors) did not
predict graft occlusion.
Hyperhomocysteinemia (HHCA) has been validated as
a graded risk factor for cardiovascular disease, independent
of other conventional risk factors.5,6 HHCA may promote
both atherogenesis and thrombosis, although the patho-
physiologic mechanisms are not understood. There is no
straightforward association of a genetic predisposition to
HHCA.5-9 Much more common than congenital homo-
cystinuria, are acquired deficiencies of cofactors for homo-
cysteine metabolism, such as vitamins B6, B12, and folate,
that cause mild HHCA.10,11 It is likely that the vascular
manifestations of HHCA are caused by the greatly elevated
serum levels of homocysteine that are characteristic of this
condition, because homocysteine is a highly reactive amino
acid that is toxic to vascular endothelium.12,13
In the present study we analyzed whether infrainguinal
bypass graft occlusion was associated with HHCA, by
comparing plasma homocysteine levels in patients with and
without graft occlusion.
From the Department of Vascular Surgery,a Julius Center for General
Practice and Patient Oriented Research,b Department of Neurology,c and
Department of Vascular Medicine,e University Medical Center Utrecht;
Department of Surgery, Hospital Amstelveend; and the Department of
Surgery, Division of Vascular and Transplant Surgery, University Medical
Center Nijmegen St Radboud.f
*A full listing of study participants is given in reference 14.
Supported by the Dutch BOA Study from the Fund Investigative Medicine
of the Dutch Health Insurance Fund Council.
Competition of interest: MJDT, who was a research fellow at the Depart-
ment of Vascular Surgery of the University Medical Center of Utrecht, the
Netherlands, for the duration of the Dutch BOA study, is currently
employed by Pharmacia, Medical Department. His present employer has
no interest in the BOA study or its publications.
Reprint requests: J. Adam van der Vliet, MD, PhD, Department of Surgery,
University Hospital Nijmegen, PO Box 9101 6500 HB Nijmegen, The
Netherlands (e-mail: J.vanderVliet@heel.azn.nl).
Copyright © 2002 by The Society for Vascular Surgery and The American
Association for Vascular Surgery.
0741-5214/2002/$35.00  0 24/1/125482
doi:10.1067/mva.2002.125482
336
PATIENTS AND METHODS
Background. All patients enrolled in the Dutch BOA
Study were eligible for the present study. In this multi-
center randomized clinical trial the effectiveness of oral
anticoagulant therapy (international normalized ratio
[INR], 3.0-4.5) and aspirin (80 mg daily) in the prevention
of occlusions and other thrombotic events after infraingui-
nal bypass grafting surgery were compared in a prospective
fashion. The background, design, and results of the trial
have been reported elsewhere.14 The study was approved
by the ethics committees of all participating hospitals. All
patients who were enrolled in the study gave written in-
formed consent. Between April 1995 and March 1998, a
total of 2690 patients were randomized. At baseline, we
recorded demographic factors, vascular history, risk factors,
clinical category of limb ischemia, operative details, and
postoperative antithrombotic medication. All patients were
evaluated 3 and 6 months postoperatively and every 6
months thereafter. Graft patency was assessed by clinical
examination and by Doppler or duplex scanning, and by
arteriography when indicated.
Purpose. The present study evaluated the influence of
(mild) HHCA on graft patency after infrainguinal bypass
surgery. Serum homocysteine levels of patients with bypass
occlusion were compared with the those levels of patients
taken from the same study population with patent bypass
grafts. The incidence of graft occlusion was related to the
postoperative collected levels of homocysteine.
Study population. The present study was designed as
a nested case-control study. The protocol was approved by
the ethics committee of the University Medical Center
Utrecht. For the cases, all patients with occlusion of the
bypass graft found at follow-up between April 1995 and
April 1997 were identified (N  150). Each case was
matched with two randomly selected controls from the
BOA Study database. All of the control subjects had patent
nonoccluded grafts. Cases and controls were matched for
age (50, 50-70, 70 years), gender, postoperative anti-
thrombotic treatment (oral anticoagulant or aspirin), site of
distal anastomosis, and graft material used (autologous vein
or nonvenous; ie, prosthetic, homogeneous, or composite
graft material).
For detection of HHCA in the study population, ve-
nous blood samples were drawn into ethylenediaminetet-
raacetic acid (EDTA)–containing vacuum tubes (Venoject
II; Terumo, Madrid) for all subjects after overnight fasting.
Blood was drawn for both cases and controls within 6
months in the same time frame. In addition, all patients
received a short questionnaire concerning diabetic status
and use of vitamin B supplements (methylcobalamin, pyri-
doxal 5-phosphate, and especially folate). Methionine
loading tests were not performed.
Laboratory homocysteine measurements. Total
plasma homocysteine (tHcy) was determined in all blood
samples. After venapuncture, blood samples were placed
immediately on ice and centrifuged within 6 hours at
3000g for 15 minutes at 4°C. Plasma was separated and
stored at 20°C until assayed for plasma total homocys-
teine determination. This methodology has previously
been demonstrated to be a reliable method of maintaining
existing plasma levels of homocysteine at the time of vena-
puncture.15 Total homocysteine concentrations were mea-
sured by high-performance liquid chromatography
(HPLC) and fluorometric detection as described by Araki
and Sako16 (intra- and interassay coefficient of variation
8%). All determinations were performed at the Labora-
tory of Metabolic Diseases, Wilhelmina Children’s Hospi-
tal, Utrecht, The Netherlands.
Interpretation of results. HHCA was defined as a
fasting homocysteine concentration exceeding the 95th
percentile of healthy controls. Initial studies on 68 healthy
laboratory controls (30 males, 38 females; mean age, 35
years; range, 18-50 years) found upper 95th percentile
values of 18.8 mol/L in males and 16.3mol/L in fe-
males. These reference values were similar to those from
other Dutch reference populations.17,18
Data analysis. Homocysteine levels are expressed as
means with standard deviations. Analysis of differences in
homocysteine concentrations between cases and controls
was performed by means of linear regression. Differences in
the frequency of patients with HHCA between cases and
controls were assessed with logistic regression and ex-
pressed as odds ratios. In both linear and logistic regression
models we controlled for any patient variables that influ-
ence the homocysteine levels. Precision of effect estimates is
described with 95% confidence interval obtained from the
regression models.
RESULTS
Demographic and clinical characteristics of cases and
controls are shown in Table I. The two groups were similar
Table I. Dutch BOA Study Group: Patient
characteristics for cases (graft occlusion) and controls
(patent grafts)
Variable
Cases
(N  150)
Controls
(N  299)
Mean age (y) 67.5  8.9 67.8  8.4
Male 63.3 62.2
History
Smoking 62.0 57.9
Diabetes mellitus 18.0 22.1
Hypertension 37.3 42.1
Hyperlipidemia 12.0 18.1
Randomized to aspirin 52.7 45.2
Mean INR in anticoagulated patients 3.14 3.24
Mean number of run-off vessels 2.0  0.9 2.1  0.9
Fem-pop bypass 76.6 78.9
Venous bypass 42.7 42.5
Time of graft occlusion
1 month 26.7 —
1-3 months 17.8 —
4-6 months 24.7 —
6 months 30.8 —
Data are percentages unless indicated otherwise.
Fem-pop, Femoro popliteal; INR, international normalized ratio.
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with regard to baseline characteristics. The allocated post-
operative antithrombotic treatment (oral anticoagulants or
aspirin) was well balanced between the groups.
We compared serum levels of homocysteine in patients
with and without graft occlusion, and no statistically signif-
icant differences were found. The mean plasma homocys-
teine level in the case group was 14.4  7.6 mol/L and
14.9  6.6 mol/L in the control group (Table II); the
resulting mean difference was 0.4 (95% CI, 1.8-0.9).
Adjustment for age, gender, and type and length of bypass
(the matching factors) did not influence the outcome (ad-
justed difference 0.4; 95% CI, 1.7-1.0). Additional
adjustment for trial medication, smoking, diabetes, hyper-
tension, hyperlipidemia, runoff, and Rutherford classifica-
tion again showed no influence on the outcome (difference
0.5; 95% CI, 1.9-0.9). Adjustment for renal function
disorder could not be performed because available data for
this factor were incomplete. Subgroup analysis showed no
relevant statistical difference in the relation between serum
homocysteine levels and graft occlusion concerning the
graft material used. Homocysteine levels higher than the
95th percentile for a normal healthy population were con-
sidered to be elevated. Twenty-eight of 150 (18.7%) pa-
tients in the case group and 65 of 299 (21.7%) patients in
the control group had levels above the 95th percentile. The
median plasma homocysteine levels in the 28 cases and 65
controls were 21.4 (interquartile range, 18.8-35.5
mol/L) and 22.7 (interquartile range, 19.9-26.0 mol/
L), respectively.
Dichotomized analysis at the 95th percentile of serum
homocysteine levels resulted in an odds ratio for HHCA of
0.81 (95% CI, 0.49-1.33). The OR was 0.82 (95% CI,
0.49-1.35) after adjustment for the matching factors. Ad-
ditional adjustment for other risk factors of occlusion re-
sulted in an OR of 0.79 (95% CI, 0.47-1.39).
The difference in homocysteine levels between cases
and controls did not depend on the material of the bypass.
Among patients with venous grafts, the mean difference
was 0 (95% CI, 1.9-1.9), whereas this difference was
0.8 (95% CI, 2.7-1.1) among patients with prosthetic
grafts. A test to determine whether these differences were
different yielded a P value of .67.
DISCUSSION
In the current nested case-control study, the postoper-
ative serum level of homocysteine proved not to be a risk
factor for graft occlusion after infrainguinal bypass grafting.
The proportion of patients with HHCA in the case group
(occluded infrainguinal bypass) did not differ significantly
from that in the control group (18.7% vs 21.7%), and mean
homocysteine levels in case and control groups were similar
(14.4  7.6 vs 14.9  6.6).
Femorodistal bypass surgery has been shown to be an
effective form of treatment for infrainguinal artery occlusive
disease. Yet the results of this treatment are imperfect, and
failure of grafts remains a matter of concern. Although the
patency rate of autologous vein grafts is favorable when
compared with prosthetic grafts, occlusion of these grafts
still occurs in 17% to 38% of the cases during the first
postoperative year.1,2,19 The etiology may be multifacto-
rial, and surgical technique and systemic patient factors are
all relevant. The identification and correction (or avoid-
ance) of factors associated with graft failure could have an
impact on patency rates. Furthermore, the identification of
factors in individual cases may define patients at high risk of
graft failure who might benefit from intensive graft surveil-
lance.
The Dutch BOA Study recently identified critical isch-
emia, femorocrural bypass, and use of nonvenous graft
material in all patients, supplemented by female gender and
poor runoff in patients with femoropopliteal bypasses, as
independent risk factors for occlusion.4 Thrombotic as well
as atherosclerotic mechanisms may be involved in the
pathogenesis. Graft occlusion during the first weeks after
bypass grafting is usually caused by thrombosis, whereas
later graft occlusion is associated with intimal hyperplasia or
more advanced atherosclerosis, often with superimposed
thrombosis.3,20,21
Since McCully22 first suggested a link between HHCA
and arteriosclerosis, firm evidence of a link between homo-
cysteine levels and peripheral vascular disease has been
reported.9,12 It has also been reported that symptomatic
patients with lower extremity disease and elevated plasma
homocysteine levels appear to have more rapid progression
of disease.23 Systemic factors such as high serum levels of
lipoprotein and homocysteine that are considered indepen-
dent risk factors for atherosclerotic coronary and peripheral
arterial disease may also influence the incidence of infrain-
guinal graft occlusion. It is likely that the vascular manifes-
tations of HHCA are caused by the greatly elevated serum
levels of homocysteine that are characteristic of this condi-
tion, because homocysteine is a highly reactive amino acid.
Table II. Dutch BOA Study Group: Homocysteine levels in cases (graft occlusion) and controls (patent graft)
Cases (N  150) Controls (N  299)
Effect estimate* (95% CI)
Crude Adjusted†
Homocysteine‡ (mol/L) 14.4  7.6 14.9  6.6 0.4 (1.8 to 0.9) 0.4 (1.7 to 1.0)
Hyperhomocysteinemia 28 (19%) 65 (22%) 0.81 (0.49 to 1.33) 0.82 (0.49 to 1.35)
*Mean difference for homocysteine level and odds ratio for hyperhomocysteinemia.
†Adjusted for age, sex, and type and length of bypass.
‡Mean  standard deviation.
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HHCA may induce dysfunction of the vascular endotheli-
um,24,25 a critical initiating event in the development of
atherosclerosis. In addition, HHCA can potentiate the
auto-oxidation of low-density lipoprotein cholesterol. It
promotes thrombosis12,26 and may stimulate proliferation
of vascular smooth muscle cells and elastinolytic processes
in the arterial wall.27,28
To our knowledge, only limited data on the influence
of homocysteine levels on graft occlusion or failure have
been published.29-32 Our present results are supported by
those of Eritsland et al,29 who found no effect of HHCA
following coronary artery bypass grafting, and Beattie et
al,30 whose results did not reveal a relation between raised
plasma homocysteine and infrainguinal venous graft failure.
No other prospective study has examined this issue, al-
though a case-control study by Irvine et al31 suggested that
HHCA is a risk factor for vein graft stenosis. Currie et al32
analyzed patients who had undergone either angioplasty or
vascular surgery; however, in their series only seven patients
had infrainguinal bypass surgery. In fact, ours is the only
study to focus on infrainguinal bypass surgery that com-
bines a prospective design with a dichotomized outcome
(patent or occluded grafts). Irvine et al focused on patients
with vein graft stenosis, and Beattie et al identified patients
with a 50% or greater stenosis of the graft. In addition, our
study is the first in which not only vein grafts but also
prosthetic grafts have been used; however, within sub-
groups according to graft material we also did not find a
relationship between homocysteine level and graft occlu-
sion. Consequently, previous studies and ours are not di-
rectly comparable, and they may focus on different patho-
genic aspects.
In all of these studies, homocysteine levels were mea-
sured directly from a single fasting blood sample deter-
mined by HPLC without the need for methionine loading.
The HPLC assay was proven to be successful, with good
reproducibility and accuracy in our laboratory, in previous
studies, and confirmed by others.15,33
The prevalence of HHCA in groups at risk of peripheral
disease ranges from 13% to 38%.5,23,25 In the study of
Beattie and colleagues,30 however, the prevalence was 57%
in patients with advanced disease, and this value was similar
to that reported by Irvine et al.31 The prevalence of (mild)
HHCA in our study (20.7%) was somewhat lower.
The cutoff point for HHCA is usually, but arbitrarily,
set at the 95th percentile of the homocysteine distribution
in healthy subjects, which, for fasting levels of homocys-
teine, corresponds to about 15 mol/L. For assessment of
mild-to-moderate forms of HHCA, the range of homocys-
teine between 15 and 100 mol/L is generally accepted.
Normal ranges vary widely in different populations, as they
are affected by several determinants (lifestyle) such as age,
gender, and folate, serum vitamin B12, serum creatinine,
and multivitamin usage.10,34,35 Already several studies have
shown that a simple therapy with vitamin B6 and folate can
normalize homocysteine metabolism.15,36,37
Our study was a nested case-control study. In a recent
review Cattaneo described 13 prospective studies (all with a
nested case-control design) of the relationship between
homocysteine and risk of cardiovascular disease. Seven
studies failed to demonstrate such an association. All these
studies were performed on previously healthy subjects, and
more recent reports with the same design all confirmed the
link between homocysteine and atherothrombosis.34,38
The present study has several limitations. First, serum
homocysteine levels were obtained from blood samples
collected postoperatively, after the occlusion of the bypass
was observed. Preoperative homocysteine levels could not
be determined because the present study was designed after
the start of the Dutch BOA Study. Second, the identifica-
tion of cases took place within a limited time, creating a
range of follow-up between operation and time of occlu-
sion; however, such variation in follow-up also existed in
the control-group. Third, all patients in our study were
receiving antithrombotic therapy, either aspirin or couma-
rin, which may have protected the grafts against harmful
effects by homocysteine; however, such preventive therapy
was given to both cases and controls.
In conclusion, our hypothesis that high perioperative
serum levels of homocysteine might contribute to graft
occlusion after infrainguinal bypass grafting could neither
be confirmed nor strongly disproved. Other factors, includ-
ing graft endothelial damage during the operation and flow
through the graft, in turn depending on the size of the
grafted artery and the extent of distal atherosclerosis, may
be strong determinants of graft occlusion. The results of
ongoing randomized double-blinded trials on the effects of
vitamins on thrombotic risk will help in defining whether
the relationship between HHCA and thrombosis is truly
causal, and to determine whether lowering blood homo-
cysteine concentrations can reduce the risk of vascular
disease.
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